• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

一名感染艾滋病毒的患者在过量服用拉替拉韦后未出现严重不良事件。

An HIV-infected Patient with No Serious Adverse Events after Overdosing on Raltegravir.

作者信息

Hosoda Tomohiro, Uehara Yuki, Naito Toshio

机构信息

Department of General Medicine, Juntendo University School of Medicine, Japan.

出版信息

Intern Med. 2020 Jan 15;59(2):285-287. doi: 10.2169/internalmedicine.3498-19. Epub 2019 Sep 18.

DOI:10.2169/internalmedicine.3498-19
PMID:31534087
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7008059/
Abstract

Patients with HIV infection represent a high-risk group for medication overdose because of the high frequency of complicating psychiatric disorders. Raltegravir is well-known for its low frequency of adverse effects. We herein report a 42-year-old Japanese man with HIV infection who was hospitalized 6 hours after overdosing with 24,000 mg of raltegravir in a suicide attempt. No serious adverse events occurred, although the plasma concentration of raltegravir at 18 hours after the overdose was 79,871.1 ng/mL. Raltegravir may be well-indicated for HIV patients at risk of overdosing.

摘要

由于并发精神疾病的频率较高，HIV感染患者是药物过量的高危人群。拉替拉韦以其不良反应发生率低而闻名。我们在此报告一名42岁的日本HIV感染男性，他在试图自杀时过量服用24000毫克拉替拉韦6小时后入院。尽管过量服用18小时后拉替拉韦的血浆浓度为79871.1纳克/毫升，但未发生严重不良事件。拉替拉韦可能适用于有药物过量风险的HIV患者。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/65fc/7008059/8b03ab46b8fe/1349-7235-59-0285-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/65fc/7008059/8b03ab46b8fe/1349-7235-59-0285-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/65fc/7008059/8b03ab46b8fe/1349-7235-59-0285-g001.jpg

相似文献

1
An HIV-infected Patient with No Serious Adverse Events after Overdosing on Raltegravir.一名感染艾滋病毒的患者在过量服用拉替拉韦后未出现严重不良事件。
Intern Med. 2020 Jan 15;59(2):285-287. doi: 10.2169/internalmedicine.3498-19. Epub 2019 Sep 18.
2
Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial.拉替拉韦 1200 毫克每日一次与拉替拉韦 400 毫克每日两次，与富马酸替诺福韦二吡呋酯和恩曲他滨联用，用于治疗未经治的 HIV-1 感染：一项随机、双盲、平行分组、Ⅲ期、非劣效性试验。
Lancet HIV. 2017 Nov;4(11):e486-e494. doi: 10.1016/S2352-3018(17)30128-5. Epub 2017 Sep 11.
3
Lack of a Clinically Significant Pharmacokinetic Interaction between Etravirine and Raltegravir Using an Original Approach Based on Drug Metabolism, Protein Binding, and Penetration in Seminal Fluid: A Pharmacokinetic Substudy of the ANRS-163 ETRAL Study.基于药物代谢、蛋白结合和精液穿透的原始方法评估依曲韦林与雷特格韦无临床显著药代动力学相互作用：ANRS-163 ETRAL 研究的药代动力学子研究。
Pharmacotherapy. 2019 Apr;39(4):514-520. doi: 10.1002/phar.2242. Epub 2019 Apr 1.
4
Raltegravir in HIV-1-Infected Pregnant Women: Pharmacokinetics, Safety, and Efficacy.拉替拉韦在感染 HIV-1 的孕妇中的药代动力学、安全性和疗效。
Clin Infect Dis. 2015 Sep 1;61(5):809-16. doi: 10.1093/cid/civ366. Epub 2015 May 5.
5
Were Additional Treatments Affecting the Pharmacokinetics Administered after Raltegravir Overdosing?在拉替拉韦过量用药后给予的其他治疗是否会影响其药代动力学？
Intern Med. 2020 May 15;59(10):1341. doi: 10.2169/internalmedicine.4246-19. Epub 2020 Feb 19.
6
Dutrebis (lamivudine and raltegravir) for use in combination with other antiretroviral products for the treatment of HIV-1 infection.度鲁比司（拉米夫定和雷特格韦），与其他抗逆转录病毒产品联合用于治疗HIV-1感染。
Expert Rev Clin Pharmacol. 2015;8(6):709-18. doi: 10.1586/17512433.2015.1090873.
7
Safety of raltegravir-based antiretroviral therapy in HIV-infected patients receiving multi-kinase inhibitors.接受多激酶抑制剂治疗的HIV感染患者中基于拉替拉韦的抗逆转录病毒疗法的安全性。
Invest New Drugs. 2017 Apr;35(2):247-249. doi: 10.1007/s10637-016-0405-0. Epub 2016 Nov 12.
8
Substitution of nevirapine or raltegravir for protease inhibitor vs. rosuvastatin treatment for the management of dyslipidaemia in HIV-infected patients on stable antiretroviral therapy (Nevrast study).在稳定接受抗逆转录病毒治疗的 HIV 感染患者中，用奈韦拉平或雷特格韦替代蛋白酶抑制剂与瑞舒伐他汀治疗血脂异常的比较（Nevrast 研究）。
Infect Dis (Lond). 2017 Oct;49(10):737-747. doi: 10.1080/23744235.2017.1339325. Epub 2017 Jul 6.
9
Dual Raltegravir-Darunavir/Ritonavir Combination in Virologically Suppressed HIV-1-Infected Patients on Antiretroviral Therapy Including a Ritonavir-Boosted Protease Inhibitor Plus Two Nucleoside/Nucleotide Reverse Transcriptase Inhibitors.在接受抗逆转录病毒治疗（包括利托那韦增强型蛋白酶抑制剂加两种核苷/核苷酸逆转录酶抑制剂）且病毒学得到抑制的HIV-1感染患者中使用多替拉韦与达芦那韦/利托那韦联合治疗。
HIV Clin Trials. 2016 Feb;17(1):38-47. doi: 10.1080/15284336.2015.1122874. Epub 2016 Jan 5.
10
Raltegravir versus lopinavir/ritonavir for treatment of HIV-infected late-presenting pregnant women.拉替拉韦与洛匹那韦/利托那韦治疗晚期就诊的HIV感染孕妇的疗效比较
HIV Clin Trials. 2018 Jun;19(3):94-100. doi: 10.1080/15284336.2018.1459343. Epub 2018 Apr 9.

引用本文的文献

1
Were Additional Treatments Affecting Pharmacokinetics Administered after Raltegravir Overdosing?: Authors' Reply.在拉替拉韦过量用药后给予的其他治疗是否会影响药代动力学？作者回复。
Intern Med. 2020 May 15;59(10):1343. doi: 10.2169/internalmedicine.4328-19. Epub 2020 Feb 19.
2
Were Additional Treatments Affecting the Pharmacokinetics Administered after Raltegravir Overdosing?在拉替拉韦过量用药后给予的其他治疗是否会影响其药代动力学？
Intern Med. 2020 May 15;59(10):1341. doi: 10.2169/internalmedicine.4246-19. Epub 2020 Feb 19.

本文引用的文献

1
Single- and Multiple-Dose Pharmacokinetics of Once-Daily Formulations of Raltegravir.拉替拉韦单剂量和多剂量的药物动力学研究。
Clin Pharmacol Drug Dev. 2018 Feb;7(2):196-206. doi: 10.1002/cpdd.358. Epub 2017 Apr 17.
2
How recent findings on the pharmacokinetics and pharmacodynamics of integrase inhibitors can inform clinical use.整合酶抑制剂的药代动力学和药效学最新研究结果如何为临床应用提供依据。
Curr Opin Infect Dis. 2017 Feb;30(1):58-73. doi: 10.1097/QCO.0000000000000327.
3
Raltegravir-induced cerebellar ataxia.拉替拉韦引起的小脑共济失调。
AIDS. 2010 Nov 13;24(17):2757. doi: 10.1097/QAD.0b013e32833fca42.
4
Long-term impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals (ACTG 5097s).依法韦仑对HIV感染者神经心理表现及症状的长期影响（艾滋病临床试验组5097s研究）
HIV Clin Trials. 2009 Nov-Dec;10(6):343-55. doi: 10.1310/hct1006-343.
5
[A case of acute renal failure involving high amounts of tenofovir after HAART start].[1例开始高效抗逆转录病毒治疗（HAART）后出现大量替诺福韦导致急性肾衰竭的病例]
Kansenshogaku Zasshi. 2008 Nov;82(6):650-3. doi: 10.11150/kansenshogakuzasshi1970.82.650.
6
Severe rhabdomyolysis associated with raltegravir use.与使用拉替拉韦相关的严重横纹肌溶解症。
AIDS. 2008 Jul 11;22(11):1382-4. doi: 10.1097/QAD.0b013e328303be40.
7
Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.健康受试者单次及多次服用拉替拉韦后的安全性、耐受性和药代动力学。
Clin Pharmacol Ther. 2008 Feb;83(2):293-9. doi: 10.1038/sj.clpt.6100281. Epub 2007 Aug 22.
8
Changing mortality rates and causes of death for HIV-infected individuals living in Southern Alberta, Canada from 1984 to 2003.1984年至2003年加拿大艾伯塔省南部HIV感染者的死亡率及死亡原因变化情况
HIV Med. 2005 Mar;6(2):99-106. doi: 10.1111/j.1468-1293.2005.00271.x.
9
Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States.美国感染人类免疫缺陷病毒的成年人中的精神疾病与药物使用情况。
Arch Gen Psychiatry. 2001 Aug;58(8):721-8. doi: 10.1001/archpsyc.58.8.721.
10
Manic syndrome associated with efavirenz overdose.与依非韦伦过量相关的躁狂综合征。
Clin Infect Dis. 2001 Jul 15;33(2):270-1. doi: 10.1086/321828.